The emerging role of exosomes in survivin secretion

Histology and Histopathology

Volumn 30, Issue 1, 2015, Pages 43-50

  Khan, Salma ^a   Bennit, Heather Ferguson ^a   Wall, Nathan R ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Exosomes; Survivin; Tumor microenvironment

Indexed keywords

BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

EXOSOME; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); TUMOR MICROENVIRONMENT;

EXOSOMES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84916608395     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Adams M., Navabi H., Croston D., Coleman S., Tabi Z., Clayton A., Jasani B. and Mason M.D. (2005). The rationale for combined chemo/immunotherapy using a toll-like receptor 3 (tlr3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 23, 2374-2378.
2. Altevogt P., Bretz N.P., Ridinger J., Utikal J. and Umansky V. (2014). Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. Semin. Cancer Biol.
3. Altieri D.C. (2003). Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22, 8581-8589.
4. Altieri D.C. (2006). The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr. Opin. Cell Biol. 18, 609-615.
5. Andersen M.H., Svane I.M., Becker J.C. and Straten P.T. (2007). The universal character of the tumor-associated antigen survivin. Clin. Cancer Res. 13, 5991-5994.
6. Anderson H.C., Mulhall D. and Garimella R. (2010). Role of extracellular membrane vesicles in the pathogenesis of various diseases, including cancer, renal diseases, atherosclerosis, and arthritis. Lab. Invest. 90, 1549-1557.
7. Andre F., Schartz N.E., Movassagh M., Flament C., Pautier P., Morice P., Pomel C., Lhomme C., Escudier B., Le Chevalier T., Tursz T., Amigorena S., Raposo G., Angevin E. and Zitvogel L. (2002). Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360, 295-305.
8. Andre F., Escudier B., Angevin E., Tursz T. and Zitvogel L. (2004). Exosomes for cancer immunotherapy. Ann. Oncol. 15, iv141-iv144.
9. Andreola G., Rivoltini L., Castelli C., Huber V., Perego P., Deho P., Squarcina P., Accornero P., Lozupone F., Lugini L., Stringaro A., Molinari A., Arancia G., Gentile M., Parmiani G. and Fais S. (2002). Induction of lymphocyte apoptosis by tumor cell secretion of faslbearing microvesicles. J. Exp. Med. 195, 1303-1316.
10. Aspe J.R., Diaz Osterman C.J., Jutzy J.M.S., Deshields S., Whang S. and Wall N.R. (2014). Enhancement of gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the survivin-t34a mutant. J. Extracell. Vesicles 3, 23244.
11. Asumen M.G., Ifeacho T.V., Cockerham L., Pfandl C. and Wall N.R. (2010). Dynamic changes to survivin subcellular localization are initiated by DNA damage. Onco Targets Ther. 3, 129-137.
12. Azmi A., Bao B. and Sarkar F. (2013). Exosomes in cancer development, metastasis, and drug resistance: A comprehensive review. Cancer Metast. Rev. 32, 623-642.
13. Bard M.P., Hegmans J.P., Hemmes A., Luider T.M., Willemsen R., Severijnen L.-A.A., van Meerbeeck J.P., Burgers S.A., Hoogsteden H.C. and Lambrecht B.N. (2004). Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am. J. Respir. Cell Mol. Biol. 31, 114-121.
14. Bendtsen J.D., Jensen L.J., Blom N., von Heijne G. and Brunak S. (2004). Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng. Des. Sel. 17, 349-356.
15. Bianco N.R., Kim S.H., Ruffner M.A. and Robbins P.D. (2009). Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheumatism 60, 380-389.
16. Denzer K., Kleijmeer M.J., Heijnen H.F., Stoorvogel W. and Geuze H.J. (2000). Exosome: From internal vesicle of the multivesicular body to intercellular signaling device. J. Cell. Sci. 113, 3365-3374.
17. Derin D., Soydinç H.O., Guney N., Tas F., Çamlıca H., Duranyıldız D., Yasasever V. and Topuz E. (2008). Serum levels of apoptosis biomarkers, survivin and tnf-alpha in nonsmall cell lung cancer. Lung Cancer 59, 240-245.
18. Dohi T., Beltrami E., Wall N.R., Plescia J. and Altieri D.C. (2004). Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J. Clin. Invest. 114, 1117-1127.
19. Dvorak H.F., Weaver V.M., Tlsty T.D. and Bergers G. (2011). Tumor microenvironment and progression. J. Surg. Oncol. 103, 468-474.
20. Ekstrom E., Bergenfelz C., von Bulow V., Serifler F., Carlemalm E., Jonsson G., Andersson T. and Leandersson K. (2014). Wnt5a induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol. Cancer 13, 88.
21. Fawzy A., Gaafar R., Kasem F., Ali S., Elshafei M. and Eldeib M. (2012). Importance of serum levels of angiopoietin-2 and survivin biomarkers in non-small cell lung cancer. J. Egypt Natl. Canc. Inst. 24, 41-45.
22. Fortugno P., Wall N.R., Giodini A., O'Connor D.S., Plescia J., Padgett K.M., Tognin S., Marchisio P.C. and Altieri D.C. (2002). Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J. Cell. Sci. 115, 575-585.
23. Fortugno P., Beltrami E., Plescia J., Fontana J., Pradhan D., Marchisio P.C., Sessa W.C. and Altieri D.C. (2003). Regulation of survivin function by hsp90. Proc. Natl. Acad. Sci. USA 100, 13791-13796.
24. Gallo A., Tandon M., Alevizos I. and Illei G.G. (2012). The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS one 7, e30679.
25. Gehrmann U., Näslund T.I., Hiltbrunner S., Larssen P. and Gabrielsson S. (2014). Harnessing the exosome-induced immune response for cancer immunotherapy. Semin. Cancer Biol. 286, 58-67.
26. Ghosh J.C., Dohi T., Kang B.H. and Altieri D.C. (2008). Hsp60 regulation of tumor cell apoptosis. J. Biol. Chem. 283, 5188-5194.
27. Ginestra A., La Placa M.D., Saladino F., Cassara D., Nagase H. and Vittorelli M.L. (1998). The amount of proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res. 18, 3433-3437.
28. Ginestra A., Miceli D., Dolo V., Romano F.M. and Vittorelli M.L. (1999). Membrane vesicles in ovarian cancer fluids: A new potential marker. Anticancer Res. 19, 3439-3445.
29. Goksel G., Taneli F., Uslu R., Ulman C., Dinc G., Coskun T. and Kandiloglu A. (2007). Serum her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer. J. Int. Med. Res. 35, 165-172.
30. Gould C.M. and Courtneidge S.A. (2014). Regulation of invadopodia by the tumor microenvironment. Cell Adhesion Migration 8, 24-23.
31. Guney N., Soydine H., Derin D., Tas F., Camlica H., Duranyildiz D., Yasasever V. and Topuz E. (2006). Serum and urine survivin levels in breast cancer. Med. Oncol. 23, 335-339.
32. Guo Q., Chen Y., Zhang B., Kang M., Xie Q. and Wu Y. (2009). Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition. Biochem. Pharmacol. 77, 1674-1683.
33. Hegmans J.P., Bard M.P.L., Hemmes A., Luider T.M., Kleijmeer M.J., Prins J.-B., Zitvogel L., Burgers S.A., Hoogsteden H.C. and Lambrecht B.N. (2004). Proteomic analysis of exosomes secreted by human mesothelioma cells. Am. J. Pathol. 164, 1807-1815.
34. Hendrix A., Westbroek W., Bracke M. and De Wever O. (2010). An ex(o)citing machinery for invasive tumor growth. Cancer Res. 70, 9533-9537.
35. Huber V., Fais S., Iero M., Lugini L., Canese P., Squarcina P., Zaccheddu A., Colone M., Arancia G., Gentile M., Seregni E., Valenti R., Ballabio G., Belli F., Leo E., Parmiani G. and Rivoltini L. (2005). Human colorectal cancer cells induce t-cell death through release of proapoptotic microvesicles: Role in immune escape. Gastroenterology 128, 1796-1804.
36. Iero M., Valenti R., Huber V., Filipazzi P., Parmiani G., Fais S. and Rivoltini L. (2008). Tumour-released exosomes and their implications in cancer immunity. Cell Death Different.15, 80-88.
37. Janowska-Wieczorek A., Wysoczynski M., Kijowski J., Marquez-Curtis L., Machalinski B., Ratajczak J. and Ratajczak M.Z. (2005). Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer 113, 752-760.
38. Johnstone R.M. (2006). Exosomes biological significance: A concise review. Blood Cells Molecules Dis. 36, 315-321.
39. Jung T., Castellana D., Klingbeil P., Cuesta Hernández I., Vitacolonna M., Orlicky D., Roffler S., Brodt P. and Zöller M. (2009). Cd44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia 11, 1093-1105.
40. Keller S, Sanderson MP, Stoeck A and Altevogt P. (2006). Exosomes: From biogenesis and secretion to biological function. Immunol. Lett. 107, 102-108.
41. Khan S., Aspe J.R., Asumen M.G., Almaguel F., Odumosu O., Acevedo-Martinez S., De Leon M., Langridge W.H. and Wall N.R. (2009). Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br. J. Cancer 100, 1073-1086.
42. Khan S., Jutzy J., Aspe J., McGregor D., Neidigh J. and Wall N. (2011a). Survivin is released from cancer cells via exosomes. Apoptosis 16, 1-12.
43. Khan S., Jutzy J.M.S., Aspe J.R., Valenzuela M.M.A., Park J.S., Turay D. and Wall N.R. (2011b). The application of membrane vesicles for cancer therapy. In: Advances in cancer therapy. Gali-Muhtasib P.H. (ed). InTech Publishing. pp 21-52.
44. Khan S., Jutzy J.M.S., Valenzuela M.M.A., Turay D., Aspe J.R., Ashok A., Mirshahidi S., Mercola D., Lilly M.B. and Wall N.R. (2012). Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS one 7, e46737.
45. Khan S., Ferguson Bennit H., Turay D., Perez M., Mirshahidi S., Yuan Y. and Wall N.R. (2014). Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC Cancer 14, 175.
46. Klinker M.W., Lizzio V., Reed T.J., Fox D.A. and Lundy S.K. (2014). Human b cell-derived lymphoblastoid cell lines constitutively produce fas ligand and secrete mhcii+fasl+ killer exosomes. Front. Immunol. 5, 144.
47. Kovar M., Boyman O., Shen X., Hwang I., Kohler R. and Sprent J. (2006). Direct stimulation of t cells by membrane vesicles from antigen-presenting cells. Proc. Natl. Acad. Sci. USA 103, 11671-11676.
48. Kucharzewska P. and Belting M. (2013). Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. J. Extracell. Vesicles 2, 20304.
49. Lehmann B.D., Paine M.S., Brooks A.M., McCubrey J.A., Renegar R.H., Wang R. and Terrian D.M. (2008). Senescence-associated exosome release from human prostate cancer cells. Cancer Res. 68, 7864-7871.
50. Lespagnol A., Duflaut D., Beekman C., Blanc L., Fiucci G., Marine J.-C., Vidal M., Amson R. and Telerman A. (2008). Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in tsap6/steap3-null mice. Cell Death Differ. 15, 1723-1733.
51. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C. and Altieri D.C. (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580-584.
52. Liu W.-S., Yan H.-J., Qin R.-Y., Tian R., Wang M., Jiang J.-X., Shen M. and Shi C.-J. (2008). Sirna directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig. Dis. Sci. 54, 89-96.
53. Lladser A., Sanhueza C., Kiessling R. and Quest A.F.G. (2011). Is survivin the potential achilles' heel of cancer? Adv. Cancer Res. 111, 1-37.
54. Mears R., Craven R.A., Hanrahan S., Totty N., Upton C., Young S.L., Patel P., Selby P.J. and Banks R.E. (2004). Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics 4, 4019-4031.
55. Milsom C., Yu J., May L., Meehan B., Magnus N., Al-Nedawi K., Luyendyk J., Weitz J., Klement P., Broze G., Mackman N. and Rak J. (2007). The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. Thromb. Res. 120 (Suppl. 2), S82-S91.
56. Mueller M.M. and Fusenig N.E. (2002). Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 70, 486-497.
57. Naumnik W., Nilklińska W., Ossolińska M. and Chyczewska E. (2009). Serum levels of hmgb1, survivin, and vegf in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem. Cytobiol. 47, 703-709.
58. Nickel W. (2003). The mystery of nonclassical protein secretion. Eur. J. Biochem. 270, 2109-2119.
59. Pennati M., Folini M. and Zaffaroni N. (2007). Targeting survivin in cancer therapy: Fulfilled promises and open questions. Carcinogenesis 28, 1133-1139.
60. Pisitkun T., Shen R.-F. and Knepper M.A. (2004). Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. USA 101, 13368-13373.
61. Reed J.C. (2001). The survivin saga goes in vivo. J. Clin. Invest. 108, 965-969.
62. Robbins P.D. and Morelli A.E. (2014). Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 14, 195-208.
63. Runz S., Keller S., Rupp C., Stoeck A., Issa Y., Koensgen D., Mustea A., Sehouli J., Kristiansen G. and Altevogt P. (2007). Malignant ascites-derived exosomes of ovarian carcinoma patients contain cd24 and epcam. Gynecol. Oncol. 107, 563-571.
64. Safaei R., Larson B.J., Cheng T.C., Gibson M.A., Otani S., Naerdemann W. and Howell S.B. (2005). Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Molecular Cancer Therap. 4, 1595-1604.
65. Shedden K., Xie X.T., Chandaroy P., Chang Y.T. and Rosania G.R. (2003). Expulsion of small molecules in vesicles shed by cancer cells: Association with gene expression and chemosensitivity profiles. Cancer Res. 63, 4331-4337.
66. Simpson R.J., Lim J.W.E., Moritz R.L. and Mathivanan S. (2009). Exosomes: Proteomic insights and diagnostic potential. Expert Rev. Proteomic 6, 267-283.
67. Swartz M.A., Iida N., Roberts E.W., Sangaletti S., Wong M.H., Yull F.E., Coussens L.M. and DeClerck Y.A. (2012). Tumor microenvironment complexity: Emerging roles in cancer therapy. Cancer Res. 72, 2473-2480.
68. Tadeo I., Berbegall A.P., Escudero L.M., Álvaro T. and Noguera R. (2014). Biotensegrity of the extracellular matrix: Physiology, dynamic mechanical balance and implications in oncology and mechanotherapy. Front. Oncol. 4, 39.
69. Tan A., De La Peña H. and Seifalian A. (2010). The application of exosomes as a nanoscale cancer vaccine. Int. J. Nanomed. 5, 889-900.
70. Tas F., Duranyildiz D., Argon A., Oguz H., Camlica H., Yasasever V. and Topuz E. (2004). Serum bcl-2 and survivin levels in melanoma. Melanoma Res. 14, 543-546.
71. Thery C., Ostrowski M. and Segura E. (2009). Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9, 581-593.
72. Villarroya-Beltri C., Baixauli F., Gutiérrez-Vázquez C., Sánchez-Madrid F. and Mittelbrunn M. (2014). Sorting it out: Regulation of exosome loading. Semin. Cancer Biol. 286, 3-13.
73. Wang J.-W., Liu Y. and Tian H.-m.Z., Wei. (2010). Effect of survivinsiRNA on drug sensitivity of osterosarcoma cell line mg-63. Chinese J. Cancer Res. 22, 68-72.
74. Wang J., Wang L., Lin Z., Tao L. and Chen M. (2014a). More efficient induction of antitumor t cell immunity by exosomes from cd40l genemodified lung tumor cells. Mol. Med. Rep. 9, 125-131.
75. Wang T., Gilkes D.M., Takano N., Xiang L., Luo W., Bishop C.J., Chaturvedi P., Green J.J. and Semenza G.L. (2014b). Hypoxiainducible factors and rab22a mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc. Natl. Acad. Sci. USA 111, E3234-E3242.
76. Wieckowski E. and Whiteside T.L. (2006). Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. Immunol. Res. 36, 247-254.
77. Wolfers J., Lozier A., Raposo G., Regnault A., Thery C., Masurier C., Flament C., Pouzieux S., Faure F., Tursz T., Angevin E., Amigorena S. and Zitvogel L. (2001). Tumor-derived exosomes are a source of shared tumor rejection antigens for ctl cross-priming. Nat. Med. 7, 297-303.
78. Xu J.-H., Wang A.-x., Huang H.-Z., Wang J.-G., Pan C.-B. and Zhang B. (2010). Survivin shrna induces caspase-3-dependent apoptosis and enhances cisplatin sensitivity in squamous cell carcinoma of the tongue. Oncol. Res. 18, 377-385.
79. Yahya R., Fouda M., El-Baz H., Mosa T. and Elmaksoud M. (2012). Serum survivin and tp53 gene expression in children with acute lymphoblastic leukemia. Iranian J. Public Health 41, 37-44.
80. Yang Y., Gao Y., Chen L., Huang Y. and Li Y. (2011). Downregulation of survivin expression and enhanced chemosensitvity of mcf-7 cells to adriamycin by pdmae/survivin shrna complex nanoparticles. Int. J. Pharmaceutics 405, 188-195.
81. Yu X., Harris S.L. and Levine A.J. (2006). The regulation of exosome secretion: A novel function of the p53 protein. Cancer Res. 66, 4795-4801.
82. Yu X., Riley T. and Levine A.J. (2009). The regulation of the endosomal compartment by p53 the tumor suppressor gene. FEBS J. 276, 2201-2212.
83. Zalatnai A. (2006). Molecular aspects of stromal-parenchymal interactions in malignant neoplasms. Curr. Mol. Med. 6, 685-693.
84. Zhang G., Miyake M., Lawton A., Goodison S. and Rosser C. (2014). Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors. BMC Cancer 14, 310.
85. Zitvogel L., Regnault A., Lozier A., Wolfers J., Flament C., Tenza D., Ricciardi-Castagnoli P., Raposo G. and Amigorena S. (1998). Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat. Med. 4, 594-600.